Circulating Tumor DNA Guided Therapeutic Strategies for CRC Patients With Small Pulmonary Nodules
NCT05495672 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100
Last updated 2022-08-10
Summary
The clinical diagnosis and treatment of small pulmonary nodules (suspected to be lung metastases) in advanced colorectal cancer patients remain controversy. Previous studies have shown that tumor-informed circulating tumor DNA (ctDNA) blood testing can sensitively detect residual cancer. Postoperative ctDNA in colorectal cancer patients is a valuable biomarker to identify minimal residual disease (MRD) after radical resection, which is possibly useful in redefining the risk group of patients and guiding postoperative treatment. This study aimed to explore the clinical value of therapeutic strategies based on tumor-informed ctDNA test in advanved colorectal cancer patients with small pulmonary nodules.
Conditions
- Advanced Colorectal Cancer
- Circulating Tumor DNA
Interventions
- PROCEDURE
-
Local treatment
Radical surgical resection, local radiotherapy, radiofrequency ablation (RFA) or interventional therapy (absolute alcohol or cryotherapy). The equipment used for RFA of lung lesions consisted of the radiofrequency generator (CelonLab POWER), cold circulation pump (Celon Aquaflow Ⅲ), radiofrequency needle electrode (Celon proSurge: T20, T30 and T40 is an electrode length of 20, 30 and 40 mm respectively, and maximum output power of 20, 30 and 40 W; Olympus Surgical Technologies Europe, Hamburg, Germany).
Sponsors & Collaborators
-
Shanghai OrigiMed Co., Ltd.
collaborator UNKNOWN -
Junjie Peng
lead OTHER
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-08-01
- Primary Completion
- 2023-12-01
- Completion
- 2025-12-01
Countries
- China
Study Locations
More Related Trials
-
Postoperative NSCLC Treated With Integrated Medicine Base on Circulating Tumor Cell Detection
NCT03269162 ·Status: UNKNOWN ·Phase: PHASE3
-
Liquid Biopsy in Advanced Oligometastatic NSCLC Receiving Surgery
NCT05648370 ·Status: UNKNOWN
-
The Establishment and Clinical Application of a Prediction Model of Lung Cancer Distant Metastasis Based on the Genomic Characteristics of Circulating Tumor Cells
NCT04568720 ·Status: UNKNOWN
-
Blood Sample Collection in Subjects With Pulmonary Nodules or CT Suspicion of Lung Cancer or Pathologically Diagnosed Lung Cancer
NCT03633006 ·Status: COMPLETED
-
Clinical Significance of Circulating Tumour Cells in Resectable Lung Cancer Patients
NCT05619562 ·Status: COMPLETED
-
3D Printing for Nodule Localization
NCT04056923 ·Status: COMPLETED ·Phase: NA
-
Using ctDNA to Determine Therapies for Lung Cancer
NCT04966663 ·Status: RECRUITING ·Phase: PHASE2
-
ctDNA as a Biomarker for Treatment in Advanced NSCLC
NCT05486988 ·Status: UNKNOWN
-
DNA Methylation Biomarkers to Predict Survival After Surgery for Lung Adenocarcinoma
NCT06477211 ·Status: COMPLETED
-
Exploration on the Value of MRD Based on ctDNA Detection in Predicting Recurrence of Resected Non-small Cell Lung Cancer
NCT05965024 ·Status: RECRUITING
-
Construction and Evaluation of the Liquid Biopsy-based Early Diagnostic Model for Lung Cancer
NCT04156360 ·Status: UNKNOWN
-
NGS-based Comprehensive Genomic ctDNA Panel in NSCLC With Immunotherapy
NCT04636047 ·Status: UNKNOWN
-
Circulating Tumor DNA Methylation Test to Differentiate Benign and Malignant Pulmonary Nodules
NCT03181490 ·Status: COMPLETED
-
A Multicenter Clinical Trial of Sputum DNA Testing for Lung Cancer in China
NCT05337163 ·Status: COMPLETED
-
Predicting Non-small Cell Lung Cancer (NSCLC) Lymph Node Metastasis: Integrating Circulating Tumor DNA (ctDNA) Mutation/ Methylation Profiling With Positron Emission Tomography-computed Tomography (PET-CT) Scan
NCT06358222 ·Status: RECRUITING
-
Circulating Tumor DNA in Patients at High Risk for Lung Cancer
NCT02715102 ·Status: TERMINATED
-
Gut Microbiota and Cancer Immunotherapy Response
NCT04682327 ·Status: UNKNOWN
-
Early Assessment of Response to Treatment of Metastatic LUng Tumors Based on CIrculating Tumor DNA
NCT03926260 ·Status: COMPLETED ·Phase: NA
-
Benign/Malignant Pulmonary Nodule Classification Based on High-throughput Whole-genome Methylation Sequencing(GM-seq)
NCT05415670 ·Status: COMPLETED
-
Circulating Tumor DNA in Surgical Lung Cancer Patients
NCT03081741 ·Status: UNKNOWN
-
ctDNA Dynamic Monitoring and Its Role of Prognosis in Stage II to IIIA NSCLC by NGS
NCT03465241 ·Status: COMPLETED
-
Cancer Panel From Blood of Lung Cancer Patients
NCT03235765 ·Status: UNKNOWN
-
SERS-Based Serum Molecular Spectral Screening for Hematogenous Metastasis
NCT06772363 ·Status: NOT_YET_RECRUITING
-
MRD Monitoring in Lung Cancer After Resection
NCT04976296 ·Status: RECRUITING
-
Detection Cell Free DNA in Lung Cancer Patients
NCT02738593 ·Status: UNKNOWN